Elewski 2006

Methods	Individual randomised controlled trials
Participants	Dx: seborrhoeic dermatitis (physician diagnosis implied from text) Exclude if patient has other skin conditions, is allergic to agents used, is pregnant, has used systemic or topical antiseborrhoeic treatment within 30 to 14 days of trial, respectively Sex: keto - male (59.4%), vehicle - male (59.1%); age: keto (52 ± 17.8), vehicle (50 ± 17.2); duration: keto (12.2 ± 13.4), vehicle (11.1 ± 12.2); previous treatment: keto (64.6%), vehicle (68.7%)
Interventions	Intervention: ketoconazole 2% gel applied once daily to face for 14 days (n = 229) Control: vehicle gel applied similarly (n = 230)
Outcomes	Symptom severity scores for erythema, pruritus and scaling
Notes	Country: United Kingdom; COI: sponsorship by Barrier Therapeutics; side effects: application site burning and erythema - keto (35), vehicle (44) This study reported symptom scores but did not provide standard deviations. For this reason, we omitted the study from the data tables and reported data in text in appropriate sections
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Baseline comparable?	Low risk	Refer to Table 1
Patient blinded?	Unclear risk	"... double-blind ..."
Provider blinded?	Unclear risk	"... double-blind ..."
Outcome assessor blinded?	Unclear risk	"... double-blind ..."
Co-interventions avoided?	Low risk	"No other topical medications or moisturizers were to be applied to affected area(s) during the study, and medicated shampoos were prohibited"
Compliance acceptable?	Unclear risk	Not reported
Drop-out acceptable?	Low risk	"... 442 (96.3%) completed the study... 222 (96.9%) in the ketoconazole group and 220 (95.7%) in the vehicle group"
Selective outcome reporting acceptable?	Unclear risk	Not reported
ITT?	Unclear risk	Not reported